Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies

Narendra Wajapeyee1,2, Romi Gupta1,2

  • 1Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama. nwajapey@uab.edu romigup@uab.edu.

Cancer Research
|September 17, 2021
PubMed

Insights

Targeted cancer therapies show initial promise but drug resistance frequently emerges. Understanding epigenetic factors driving resistance is crucial for developing effective treatments for drug-resistant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Cancer involves complex genetic and epigenetic alterations.
  • Targeted therapies based on driver oncogenes offer effective treatments for various cancers.
  • Therapeutic resistance is a significant clinical challenge.

Purpose of the Study:

  • To review mechanisms of resistance to targeted cancer therapeutics.
  • To highlight the role of epigenetic factors in driving drug resistance.
  • To discuss implications for preventing and treating drug-resistant cancers.

Main Methods:

  • Analysis of large-scale sequencing data from patient-derived cancer samples.
  • Review of studies identifying molecular alterations conferring resistance.
  • Elaboration on epigenetic factors and oncogenic pathways.

Main Results:

  • Targeted therapies can lead to robust initial responses but resistance often develops.
  • Mechanisms of resistance include alterations in transcriptome, transcription factors, DNA, and chromatin regulators.
  • Epigenetic alterations are key drivers of drug resistance and oncogenic pathways.

Conclusions:

  • Understanding resistance mechanisms is vital for overcoming therapeutic limitations.
  • Epigenetic modifications play a critical role in acquired drug resistance.
  • This knowledge has direct implications for developing novel strategies against drug-resistant cancers.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K